Table 1 Seroprevalence of HPyV6 and HPyV7 antibodies in serum using ELISA or Luminex platform
From: Emerging role of human polyomaviruses 6 and 7 in human cancers
Source of the specimen | Age (y) | Samples n | HPyV6 Positive n (%) | HPyV7 Positive n (%) | Assay | Reference | ||
|---|---|---|---|---|---|---|---|---|
VLP | GST | VLP | GST | |||||
18–65 (y) Blood donors. < 18 or > 65 (y) From discarded lab samples | 1–4 | 48 | 18 (37.5) |  | 5 (10.4) |  | ELISA | [39] |
5–9 | 69 | 40 (57.9) |  | 23 (33.3) |  | |||
10–14 | 92 | 65 (70.6) |  | 41 (44.6) |  | |||
15–19 | 89 | 55 (61.8) |  | 32 (36) |  | |||
20–29 | 49 | 43 (87.8) |  | 22 (44.9) |  | |||
30–39 | 73 | 49 (67.1) |  | 31 (42.5) |  | |||
40–49 | 105 | 89 (84.8) |  | 62 (59.1) |  | |||
50–59 | 95 | 78 (82.1) |  | 64 (67.4) |  | |||
60–69 | 100 | 88 (88) |  | 68 (68) |  | |||
70–79 | 52 | 46 (88.5) |  | 42 (80.8) |  | |||
≥ 80 | 56 | 55 (98.2) |  | 48 (85.7) |  | |||
Blood donors | 20–29 | 96 | 82 (85.4) | 77 (80.2) | 58 (60.4) | 68 (70.8) | ELISA | [37] |
30–39 | 129 | 114 (88.4) | 111 (86) | 92 (71.3) | 106 (82.2) | |||
40–49 | 52 | 48 (92.3) | 48 (92.3) | 32 (61.5) | 40 (76.9) | |||
50–59 | 24 | 22 (91.7) | 21 (87.5) | 16 (66.7) | 19 (79.2) | |||
> 59 | 5 | 4 (80) | 4 (80) | 3 (60) | 4 (80) | |||
Serum obtained for routine lab tests | 0–0.5 | 31 |  | 25 (80.6) |  | 18 (58.1) | Luminex platform | [40] |
0.6–1.9 | 63 |  | 14 (22.2) |  | 12 (19) | |||
2–3 | 62 |  | 21 (33.9) |  | 12 (19.4) | |||
4–5 | 58 |  | 26 (44.8) |  | 19 (32.8) | |||
6–7 | 58 |  | 29 (50) |  | 21 (36.2) | |||
8–9 | 70 |  | 44 (62.9) |  | 27 (38.6) | |||
10–14 | 55 |  | 31 (56.4) |  | 21 (38.2) | |||
15–19 | 59 |  | 38 (64.4) |  | 25 (42.4) | |||
20–29 | 59 |  | 39 (66.1) |  | 30 (50.8) | |||
30–39 | 64 |  | 41 (64.1) |  | 35 (54.7) | |||
40–49 | 54 |  | 34 (63) |  | 33 (61.1) | |||
50–59 | 58 |  | 46 (79.3) |  | 36 (62.1) | |||
60–69 | 54 |  | 50 (92.6) |  | 45 (83.3) | |||
> 70 | 54 |  | 50 (92.6) |  | 46 (85.2) | |||
Blood donors | 18–29 | 208 |  | 156 (75.7) |  | 117 (56.8) | Luminex platform | [38] |
30–39 | 209 |  | 175 (84.5) |  | 154 (74.4) | |||
40–49 | 208 |  | 173 (83.6) |  | 155 (74.9) | |||
50–59 | 215 |  | 184 (85.6) |  | 154 (71.6) | |||
60–69 | 210 |  | 187 (89.5) |  | 169 (80.9) | |||
Blood donors | Â | 95 | 66 (69) | Â | 33 (35) | Â | ELISA | [23] |
SCCs transplanted cases | Â | 110 | Â | 65 (59) | Â | 57 (51.8) | ELISA and Luminex platform | [42] |
Non-SCCs transplanted cases | Â | 207 | Â | 137 (66.2) | Â | 85 (41) | ||
Lung cancer | Â | 511 | 393 (76.9) | Â | 333 (65.2) | Â | Luminex platform | [43] |
Controls | Â | 508 | 400 (78.7) | Â | 334 (65.8) | Â | ||